



WT
KO
CHIR:
-
+
-
+
1.0
2.6
β-catenin
Vinculin

(A)


SP5
Relative Gene Expression
10
8
6
4
2
0
CHIR: - + + + + + + + - + + + + + + +
Agent (uM): 0 0 1 5 1 5 1 5 0 0 1 5 1 5 1 5
WT
KO

(B)

FIG. 1



(C)

FIG. 1 (CONTINUED)





DMSO
I-470
I-66
β-catenin
HDAC2
Total β-catenin in nuclear fraction
(24h)
β-catenin / HDAC2
1.5
1.0
0.5
0.0
DMSO
I-470
I-66

FIG. 2



CTG
(6-day treatment)
% Viability to DMSO
120
100
80
60
40
20
0
0.01
0.1
1
10
100
Concentration (μM)
Peptide A
I-66
I-470
IC50: 0.7μM
IC50: 4.0μM

(A)



Relative Gene Expression
1.5
1.0
0.5
0.0
0.01
0.1
1
10
100
Concentration (μM)
Peptide A
I-66
I-470
IC50:
0.3μM
IC50:
1.4μM

(B)

FIG. 3



(C)



(D)

FIG. 3 (CONTINUED)





Vehicle
I-66, 30 mg/kg, Q4D
I-66, 75 mg/kg, Q4D
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
Days post 1st dose

FIG. 4



i.p. 50 mg/kg
Plasma PK
Tumor PK
Concentration (μM, Log10)
1000
100
10
1
0.1
0
24
48
72
96
120
Time (h)

(A)

FIG. 5



(B)



(C)

FIG. 5 (CONTINUED)



I-66, 1H NMR, d6-DMSO, 373 K
f1 (ppm)
.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
13000
14000
15000
16000
17000
18000
19000
20000
21000
22000

FIG. 6





1H NMR, d6-DMSO, 373 K
1.94
0.94
0.96
3.95
2.50
1.48
3.49
4.54
1.07
1.25
6.46
2.19
0.90
0.99
2.02
1.00
3.16
1.10
1.24
7.79
2.81
2.55
1.71
3.34
6.56
2.47
4.24
3.37
1.02
1.06
2.32
9.74
3.50
3.18
3.49
5.56
3.08
4.05
4.02
6.26
7.10
1.33
9.56
1.01
.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
13000
14000
15000
16000
17000
18000
19000
20000
21000
22000

FIG. 7


2000
1500
1000
500
0
Tumor Volume (mm3)
Vehicle
I-66 (50 mg/kg)
0
10
20
30
40
50
Days of treatment

(A)


Vehicle Control
I-66 (60 mg/kg)
1600
1400
1200
1000
800
600
400
200
0
Tumor Volume (mm3)
0
10
20
30
Days of treatment

(B)

FIG. 8